<DOC>
	<DOCNO>NCT02658422</DOCNO>
	<brief_summary>This study conduct determine whether test product ( GW483100 10 mg contain montelukast sodium equivalent 10 mg montelukast ) bioequivalent reference montelukast sodium 10 mg tablet ( innovator product ) healthy adult volunteer fast condition . This open-label , balance , randomize , single dose , two-way crossover study , enrol 32 healthy human subject ensure least 28 subject complete study . Each subject enrol participate two treatment period separate washout period least 7 day 14 day dose occasion . Total duration study subject approximately 7 week screen subject 's last visit .</brief_summary>
	<brief_title>Bioequivalence GW483100 10 Milligram ( mg ) Tablets Healthy Subjects Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Between 18 65 year age inclusive , time signing informed consent . Healthy , non smoker , determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator consultation Medical Monitor require agree document find unlikely introduce additional risk factor interfere study procedure . Body weight &gt; =50 kilogram ( kg ) body mass index ( BMI ) within range 19 24.9 kg/square meter ( m^2 ) ( inclusive ) Healthy male female subject : MALES : Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication 24 hour last dose study medication . . ) Vasectomy documentation azoospermia . b . ) Male condom plus partner use one contraceptive follow option : contraceptive subdermal implant ; intrauterine device intrauterine system ; oral contraceptive , either combined progestogen alone ; injectable progestogen ; contraceptive vaginal ring ; percutaneous contraceptive patch . FEMALES : Eligible participate , pregnant ( confirmed negative serum human chorionic gonadotrophin [ hCG ] test ) , lactate , least one follow condition applies : . ) Nonreproductive potential define : Premenopausal females one following : document tubal ligation , document hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , hysterectomy , Documented Bilateral Oophorectomy Postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] estradiol level consistent menopause ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . b . ) Reproductive potential agrees follow one option list Modified List Highly Effective Methods Avoiding Pregnancy Females Reproductive Potential ( FRP ) 30 day prior first dose study medication 24 hour last dose study medication completion followup visit . Capable give sign informed consent describe protocol include compliance requirement restriction list consent form protocol . Alanine aminotransferase ( ALT ) bilirubin &gt; 1.5xupper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Corrected QT ( QTc ) &gt; 450 millisecond ( msec ) NOTES : The QTc QT interval correct heart rate accord Bazett 's formula ( QTcB ) , Fridericia 's formula ( QTcF ) , and/or another method , machineread manually overread ; The specific formula use determine eligibility discontinuation individual subject determine prior initiation study . In word , several different formula use calculate QTc individual subject low QTc value use include discontinue subject trial ; For purpose data analysis , QTcB , QTcF , another QT correction formula , composite available value QTc use specify Reporting Analysis Plan ( RAP ) . No concomitant medication take subject participate study . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram ( g ) alcohol : halfpint ( ~240 milliliter [ mL ] ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Presence hepatitis B surface antigen ( HBsAg ) , positive hepatitis C antibody test result screen within 3 month prior first dose study treatment . A positive prestudy drug/alcohol screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Where participation study would result donation blood blood product excess 500 mL within 90 day . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 90 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Gastrointestinal disease gastrointestinal surgical history affect absorption investigational drug . Any symptom systolic BP &lt; 95 millimeter mercury ( mmHg ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>